Wegovy Alternatives (2026): Zepbound, Foundayo, Saxenda & Cheaper Compounded Semaglutide Options

Wegovy (semaglutide 2.4 mg, Novo Nordisk) is the canonical first-line FDA-approved chronic weight management injection — STEP-1 (Wilding NEJM 2021, PMID 33567185) reported −14.9% mean body-weight change at 68 weeks. Patients searching “Wegovy alternatives” in 2026 are typically asking one of four distinct questions: (1) higher-effect (the answer is Zepbound), (2) oral instead of injection (Foundayo), (3) cheaper monthly cash-pay (the manufacturer self-pay channel, generic liraglutide, or compounded semaglutide with regulatory caveats), or (4) non-GLP-1 entirely (Qsymia, Contrave, Xenical/alli). The right alternative depends on which goal you are solving for. Here is the structured answer with verbatim FDA-label data and verified 2026 prices.

Why patients seek Wegovy alternatives

Wegovy is the FDA-approved gold standard for chronic weight management injection, but four real-world pressures push patients toward alternatives:

• Cost. Wegovy retail cash price is ~$1,349/month before manufacturer programs. NovoCare self-pay drops this to $299/month for the standard pen, but only for patients who pay cash directly. Insured patients with high deductibles or non-covered plans face the retail price until the deductible is met.
• GI side effects. The Wegovy §6.1 Adverse Reactions table reports nausea in ~44%, diarrhea ~30%, vomiting ~24%, constipation ~24% during the STEP-1 treatment period. A meaningful subset cannot tolerate dose escalation past 1.7 mg or 2.4 mg.
• Formulary changes. CVS Caremark removed Zepbound from most commercial formularies effective July 2025 in favor of Wegovy as the single preferred GLP-1 for weight management. This swap forced many patients FROM Zepbound TO Wegovy — the opposite direction of most alternative searches. Patients on Wegovy by formulary forcing function may want to switch BACK to Zepbound for the higher effect size; see our GLP-1 insurance-dropped coverage appeal playbook.
• Plateau. Patients who reach a weight-loss plateau on Wegovy 2.4 mg sometimes seek a higher-effect alternative. The FDA-approved option here is the higher-effect Wegovy HD 7.2 mg pen (approved September 2025, dose-escalation past 2.4 mg) or switching to Zepbound (different molecule, dual GIP/GLP-1 agonist).

With those drivers in mind, the right alternative depends on which problem you are solving. Pick the goal that matches yours and skip to that section.

Quick comparison: every FDA-approved Wegovy alternative

Cross-trial efficacy comparisons are indirect — STEP-1, SURMOUNT-1, ATTAIN-1, SCALE, and CONQUER enrolled different populations and ran different durations. The only direct head-to-head trial in the chronic weight-management class is SURMOUNT-5 (tirzepatide vs semaglutide); see §Higher-effect alternative below for the verbatim trial frame.

Higher-effect alternative: Zepbound (tirzepatide)

If you are on Wegovy and want greater mean weight loss, Zepbound (tirzepatide, Eli Lilly, the weight-management-indicated brand of the same molecule marketed for type 2 diabetes as Mounjaro) is the FDA-approved higher-effect option. The cross-trial efficacy data is unambiguous in its direction:

• Wegovy STEP-1 (Wilding NEJM 2021, PMID 33567185): −14.9% mean body-weight change at 68 weeks on semaglutide 2.4 mg.
• Zepbound SURMOUNT-1 (Jastreboff NEJM 2022, PMID 35658024): −20.9% mean body-weight change at 72 weeks on tirzepatide 15 mg; −19.5% on 10 mg; −15.0% on 5 mg.
• Direct head-to-head: SURMOUNT-5 (Aronne NEJM 2025, PMID 40353578): tirzepatide produced greater mean weight loss than semaglutide in a randomized direct comparison in adults with obesity without diabetes — the first FDA-quality head-to-head trial across the two molecules in chronic weight management.

The catch — and it is a real one. Switching from Wegovy to Zepbound is not a simple prescription rewrite:

• New prior authorization required. Most PBM formularies have Wegovy and Zepbound on different tiers, with separate PA criteria. CVS Caremark removed Zepbound from most commercial formularies effective July 2025; the appeal pathway varies by plan. See our Aetna GLP-1 PA guide and Cigna GLP-1 PA guide.
• Re-titration ladder. Per the Zepbound §2.2 dosing label, all patients start at 2.5 mg weekly for 4 weeks, then escalate by 2.5 mg increments. Patients switching from Wegovy 2.4 mg do not skip ahead — they start at Zepbound 2.5 mg from week 1. Expect a temporary dip in appetite suppression during re-titration.
• Side-effect reset. Even patients who tolerated Wegovy maintenance may experience renewed GI adverse events on Zepbound starting dose. This is not a class-tolerance failure; it is the expected adaptation window for the new molecule.
• Different copay savings program. Eli Lilly's Zepbound copay savings card has separate eligibility criteria and dollar caps from Novo Nordisk's Wegovy copay savings card. Verify eligibility before switching. For verbatim cost comparison see our Zepbound vs Wegovy cost comparison.

For the verbatim §2 dose ladders on both labels, the switch-equivalence framework, and what side effects to expect on the new starting dose, see our Wegovy ↔ Zepbound switch dose-equivalence guide. For side-effect comparison see Zepbound vs Wegovy side effects.

Oral alternative: Foundayo (orforglipron)

If you want to leave injectable therapy entirely, Foundayo (orforglipron, Eli Lilly, FDA-approved April 1, 2026) is the first FDA-approved oral medication for chronic weight management in the GLP-1 era. It is the answer to the pure “oral instead of injection” question.

• Class. Foundayo is a non-peptide small-molecule GLP-1 receptor agonist — not a peptide drug like semaglutide. Per the Foundayo §12.1 label mechanism-of-action language, orforglipron binds the GLP-1 receptor and produces glucose-dependent insulin secretion, slowed gastric emptying, and central appetite reduction analogous to injectable GLP-1s.
• Efficacy — ATTAIN-1. The pivotal phase 3 trial (Wharton NEJM 2025, PMID 40960239) reported −11.1% mean body-weight change at 72 weeks on the 17.2 mg labeled-max dose in adults with obesity without type 2 diabetes. That places Foundayo between Saxenda (~−8%) and Wegovy (~−14.9%) in cross-trial indirect comparison — meaningfully less effective than Wegovy but the only FDA-approved oral option in the GLP-1 weight-management class.
• Dosing. Once-daily oral tablet. No fasting restrictions analogous to Rybelsus (which requires fasted administration with ≤4 oz water and a 30-minute wait before food or other oral medications). Foundayo can be taken with or without food.
• Cost. $149/month at LillyDirect Self Pay Pharmacy or Amazon Pharmacy as of 2026-05-09. This is the cheapest brand-name oral GLP-1 path on the market.
• Side effects. Per the Foundayo §6.1 Adverse Reactions table, GI events (nausea, diarrhea, vomiting) are the most common — consistent with GLP-1 class but in many patients milder than the injectable subcutaneous depot delivery profile, because oral absorption produces a different pharmacokinetic curve.

For the deeper Foundayo evidence walkthrough, see Foundayo vs Wegovy vs Zepbound comparison. For the broader oral-peptide-vs-Foundayo landscape see best oral peptides for weight loss: evidence vs hype.

Older injectable alternative: Saxenda (liraglutide) — and the new Teva generic

If cost is the dominant constraint and a daily injection is acceptable, Saxenda (liraglutide 3 mg, Novo Nordisk, FDA-approved December 23, 2014) is the original injectable GLP-1 receptor agonist for chronic weight management. The 2026 reason to consider Saxenda is the price disruption from a brand-new FDA-approved generic.

• Efficacy — SCALE Obesity and Prediabetes. The pivotal phase 3 trial (Pi-Sunyer NEJM 2015, PMID 26132939; n=3,731, 56 weeks) reported −8.0% mean body-weight change on liraglutide 3 mg vs −2.6% on placebo. 63.2% of liraglutide patients lost at least 5% of baseline body weight vs 27.1% on placebo. SCALE Diabetes (Davies JAMA 2015, PMID 26284720) replicated −6.0% in T2D patients.
• Dosing burden. Once-DAILY injection (NOT once-weekly like Wegovy and Zepbound). For patients who experience injection fatigue, this is a meaningful downgrade in convenience.
• Effect size. Saxenda's ~8% body-weight loss is the smallest published primary endpoint in the FDA-approved injectable GLP-1 weight-loss class. In cross-trial indirect comparison it is meaningfully less effective than Wegovy (~14.9%) and Zepbound (~20.9%).
• Generic availability — the August 2025 watershed. Teva Pharmaceuticals received FDA approval on August 28, 2025 for generic liraglutide 3 mg specifically referencing Saxenda for chronic weight management. This is the FIRST FDA-approved generic GLP-1 receptor agonist for weight management in the United States and a meaningful price-disruption opportunity in the class.
• Aetna's 4% continuation rule. Aetna's clinical policy bulletin 1227-C uses a 4% body-weight loss threshold at month 4 for Saxenda continuation — not the standard 5% used for Wegovy and Zepbound. Verify with the verbatim policy text before relying on this for an appeal.
• Class boxed warning. Saxenda carries the standard GLP-1 class boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies; the same warning appears on Wegovy, Ozempic, Mounjaro, and Zepbound labels.

For the full Saxenda evidence walk plus the verbatim Teva generic approval announcement, see our Saxenda (liraglutide) FDA label, SCALE evidence & Teva generic update.

Compounded semaglutide as a cash-pay alternative

With the regulatory caveat above noted, compounded semaglutide from licensed 503A pharmacies typically runs $99–$300/month — meaningfully below NovoCare's $299/month standard pen for some compounded products, and well below the manufacturer list-price retail of ~$1,349/month.

• What you get. Compounded semaglutide is typically a multi-dose vial requiring patient reconstitution with bacteriostatic water and self-injection with provided syringes. Dose is specified by the prescriber per a titration schedule; compounded products often offer non-standard doses (e.g., 0.1 mg or 3.5 mg) not available in Wegovy or Ozempic pen increments.
• What you do not get. Lot-by-lot FDA quality oversight, the cold-chain pen device, the §6 Adverse Reactions surveillance database that drives FDA labeling updates, or the manufacturer copay assistance card eligibility.
• Verification. Before paying any compounded-semaglutide telehealth invoice, verify the dispensing pharmacy is licensed in your state via your state board of pharmacy lookup, has LegitScript Healthcare Merchant Certification, and is not on the NABP “Not Recommended Sites” list. See our online pharmacy legitimacy verification guide for the four-check workflow (LegitScript, NABP, FDA Warning Letters, state board) — the same workflow applies to compounded semaglutide vendors.

For the ranked-and-vetted compounded semaglutide directory, see our cheapest compounded semaglutide guide and the compounded semaglutide provider directory. We do not name grey-market vendors that operate outside the licensed-pharmacy framework.

Non-GLP-1 alternatives

If you cannot tolerate the GI side effects of GLP-1s, cannot access them due to insurance, or prefer an oral pill route outside the GLP-1 class, the FDA-approved non-GLP-1 anti-obesity medications are:

• Qsymia (phentermine + topiramate ER) — FDA-approved July 2012 for chronic weight management. Once-daily capsule. Schedule IV controlled (phentermine component). REMS program for fetal toxicity from the topiramate component. Mean weight loss ~9–11% at 56 weeks (CONQUER + EQUIP trials) at the top dose of 15 mg phentermine / 92 mg topiramate ER. Per the Qsymia DailyMed label (SetID 40dd5602-53da-45ac-bb4b-15789aba40f9), discontinue if patient has not lost at least 3% baseline body weight after 12 weeks at the recommended dose.
• Contrave (naltrexone + bupropion ER) — FDA-approved September 2014 for chronic weight management. Twice-daily tablet escalation (one tab/day week 1 to four tabs/day week 4). Boxed warning for suicidality (bupropion component). Mean weight loss ~5–9% at 56 weeks (COR-I, COR-II, COR-BMOD trials).
• Xenical (orlistat 120 mg, Rx) / alli (orlistat 60 mg, OTC) — FDA-approved 1999 (Rx) and 2007 (OTC). Three times daily with meals. Acts locally in the gut to inhibit pancreatic lipase and reduce dietary fat absorption ~30%. Modest weight loss (~3–5% at 1 year) and significant tolerability challenge from oily stools, fecal urgency, and oily spotting if dietary fat is not reduced.
• Phentermine monotherapy — FDA-approved 1959. Schedule IV. Short-term use only (up to 12 weeks per the FDA label). Sympathomimetic stimulant. Not equivalent to chronic weight management; covered here only because it is sometimes substituted by patients seeking a non-GLP-1 oral route. See our Lomaira (phentermine 8 mg TID) evidence guide for the verbatim short-term phentermine class data.

For the deeper non-GLP-1 vs GLP-1 evidence comparison, see our FDA-approved weight loss medications hub.

What “cheaper Wegovy” actually means in 2026

Many patients searching “Wegovy alternatives” actually want the same Wegovy molecule but at a lower monthly out-of-pocket. The verified 2026 channels (in price order):

• NovoCare Pharmacy self-pay — Wegovy standard pen $299/month (verified 2026-05-09; the older $499/month figure is outdated). Wegovy oral pill 1.5/4 mg $149/month through Aug 31, 2026. Wegovy HD 7.2 mg pen $399/month. Direct from manufacturer, no insurance navigation.
• $25 manufacturer copay savings card — commercially insured patients meeting the Wegovy Savings Card eligibility (commercial/private insurance covering Wegovy, not government-insured) can fill at $0–$25/month for the first 12 fills, capped at the program annual maximum benefit. Per the Novo Nordisk program terms.
• Sam's Club Plus Pharmacy — oral Wegovy 1.5 mg at $149/month (launched January 2026); Wegovy + Ozempic injection pens at $499/month via the Novo Nordisk Copay Savings Program for Plus members. Free same-day refrigerated delivery for Plus members.
• Costco Member Prescription Program (CMPP) via Sesame — Wegovy at $349/month for Costco members. New patient $199/month for first 2 months. Membership-gated for the discount; non-members can fill at posted cash price by federal pharmacy access law.
• GoodRx coupons — Wegovy oral pill 1.5 mg at $149/month manufacturer-funded (through April 15, 2026). Wegovy injection pen via GoodRx is ~$1,300+ retail with single-digit coupon discounts — this is NOT a competitive cash-pay path for the injection pen. See our Wegovy GoodRx + cash-pay coupon channel guide for the channel-by-channel detail.
• Compounded semaglutide — $99–$300/month from licensed 503A pharmacies, with the regulatory caveats described above. Not FDA-approved and not equivalent to brand-name Wegovy in the regulatory sense.

For the full live channel-by-channel pricing across every brand, see our GLP-1 pricing index which is refreshed monthly.

If you were formulary-displaced FROM Wegovy

A subset of patients searching “Wegovy alternatives” had their Wegovy prescription dropped by their insurer and are looking for what to do next. The most common precipitating events in 2026:

• Plan formulary swap. Some commercial plans switched preferred GLP-1 from Wegovy to a different drug or removed weight-management coverage entirely.
• BMI clawback. Some plans require annual re-attestation of BMI ≥30 (or ≥27 with comorbidity) for continued coverage; patients who lost enough weight to drop below the cut-off get cut off.
• Continuation-rule failure. Most plans require ≥5% body-weight loss at month 4 (Aetna uses 4% for Saxenda specifically) to continue coverage. Patients who do not hit the threshold get denied for continuation.

For each of these events, the appeal pathway and the next-best alternative differ. The full playbook with letter of medical necessity templates and step-by-step PA appeal framework is at GLP-1 insurance-dropped coverage appeal playbook.

For patients on Wegovy off-label for type 2 diabetes

A small subset of patients use Wegovy off-label for type 2 diabetes glycemic control instead of (or in addition to) weight loss. This is uncommon because Wegovy is the weight-management-indicated brand of semaglutide and the diabetes-indicated brand (Ozempic) is the same molecule with a lower max dose (2 mg vs 2.4 mg). If you are in this scenario, the right alternative is structurally different — you want a T2D-indicated GLP-1, not a weight-management-indicated one.

For the T2D-anchored alternative discussion (Mounjaro, Trulicity, Rybelsus, Victoza + generic liraglutide), see our companion article: Ozempic alternatives (2026): the T2D-anchored GLP-1 guide. And for the Wegovy-vs-Mounjaro decision-tree across the two indications, see Wegovy vs Mounjaro decision guide.

Bottom line

• Want greater weight loss than Wegovy? → Zepbound (tirzepatide). Different molecule, −20.9% in SURMOUNT-1 vs Wegovy's −14.9% in STEP-1. Direct head-to-head SURMOUNT-5 (NEJM 2025) confirmed tirzepatide superior. Requires new PA + re-titration from 2.5 mg.
• Want oral instead of injection? → Foundayo (orforglipron). First FDA-approved oral medication for chronic weight management in the GLP-1 era. −11.1% at 17.2 mg in ATTAIN-1. $149/month at LillyDirect or Amazon Pharmacy.
• Want the cheapest brand-name GLP-1 path? → Saxenda generic (Teva, August 2025) for daily injection, or Foundayo $149/month for daily oral, or Wegovy NovoCare self-pay $299/month for the same molecule at weekly cadence.
• Cannot tolerate any GLP-1? → Qsymia (~9.8% at top dose), Contrave (~5–9%), or Xenical/alli (~3–5%). All oral, all non-GLP-1.
• Want compounded semaglutide as a cash-pay option? → Available from licensed 503A pharmacies $99–$300/month, with the FDA enforcement-discretion grace-period caveat (ended February 2025). Not equivalent to FDA-approved Wegovy. Verify the dispensing pharmacy via the four-check workflow before paying any invoice.

Related research

• Weight loss injections guide — every FDA-approved option, effectiveness, cost, safety — the upstream discovery article for readers searching generic terms like “weight loss injections” or “best weight loss shot” before they’ve decided on Wegovy specifically. Anchors the full FDA-approved menu (Wegovy, Zepbound, Saxenda) plus the off-label T2D injectables and the investigational pipeline.
• Zepbound vs Wegovy cost comparison — verbatim NovoCare and LillyDirect 2026 prices across every dose.
• Zepbound vs Wegovy side effects — the §6 Adverse Reactions tables compared head-to-head.
• Wegovy ↔ Zepbound switch dose-equivalence guide — verbatim §2 dose ladders and re-titration logic.
• Wegovy GoodRx + cash-pay coupon channel guide — channel-by-channel monthly cost detail.
• GLP-1 insurance-dropped coverage appeal playbook — LMN templates and PA appeal pathways.
• Saxenda (liraglutide) FDA label, SCALE evidence & Teva generic update
• Foundayo vs Wegovy vs Zepbound comparison
• Ozempic alternatives (T2D-anchored companion article)
• North Carolina Medicaid GLP-1 coverage (2026): the double-reversal state — NC is the first and only state Medicaid program in the 9-state series where Wegovy is listed as Preferred for the chronic-weight-management indication. As the Preferred product on the NC Medicaid PDL, Wegovy is the first-line GLP-1 weight-management drug before Saxenda or Zepbound can be approved (step therapy: T/F of Wegovy or documented contraindication required for Non-Preferred alternatives). NC is the counter-example to the seven exclusion-pattern states.